Summary & Overview
CPT 92522: Evaluation of Speech Sound Production
CPT code 92522 represents the evaluation of speech sound production, a fundamental procedure in speech-language pathology for diagnosing articulation, phonological, apraxia, and dysarthria disorders. This code is widely used in outpatient settings by speech-language pathologists to assess patients with communication challenges. Nationally, the code is recognized by major payers including Aetna, Blue Cross Blue Shield, Cigna Health, Medicare, and UnitedHealthcare, ensuring broad coverage for individuals seeking speech evaluation services.
This publication provides a comprehensive overview of 92522, detailing its clinical context, payer coverage, and its role in the broader landscape of speech-language pathology services. Readers will gain insights into the typical site of service, the types of clinical conditions evaluated, and how this code fits within related procedures such as treatment and group therapy. The summary also highlights relevant policy updates and benchmarks, offering a clear understanding of how 92522 is utilized across the healthcare system. The information is designed to support stakeholders in understanding the importance and scope of speech sound production evaluation in clinical practice.
CPT Code Overview
CPT code 92522 is used for the evaluation of speech sound production, including conditions such as articulation disorders, phonological process issues, apraxia, and dysarthria. This code falls under the Speech‑Language Pathology / Otorhinolaryngologic Evaluation and Procedures service type. The typical site of service for this evaluation is an outpatient setting, most often in the office of a Speech‑Language Pathologist. This assessment is a critical step in identifying and planning treatment for individuals with speech sound production difficulties.
Clinical & Coding Specifications
Clinical Context
A patient, often referred by an otolaryngologist or primary care provider, presents to a speech-language pathologist in an outpatient setting (such as a therapy office). The patient may have a history of oropharyngeal cancer, such as a malignant neoplasm of the tonsil or epiglottis, and is experiencing difficulties with speech sound production. The speech-language pathologist conducts a comprehensive evaluation to assess articulation, phonological processes, apraxia, or dysarthria. This evaluation helps determine the nature and severity of the speech disorder, guiding further treatment planning.
Coding Specifications
- Modifier
GN: Indicates that the service is part of a speech-language pathology plan of care. Used when billing speech-language pathology services to payors such as Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
| Modifier | Description |
|---|---|
GN | Speech-Language Pathology services modifier |
- Provider Taxonomies:
| Taxonomy Code | Specialty |
|---|---|
235Z00000X | Speech-Language Pathologist |
2355S0801X | Speech-Language Pathologist, School |
2355S0803X | Speech-Language Pathologist, Public Health |
These taxonomies represent professionals qualified to perform speech sound production evaluations in various settings, including clinical, school, and public health environments.
Related Diagnoses
C09.0: Malignant neoplasm of tonsillar fossa- Relevant as patients with this diagnosis may develop speech sound production difficulties due to tumor location or treatment effects.
C09.1: Malignant neoplasm of tonsillar pillar (anterior) (posterior)- Speech disorders may arise from structural or functional changes in the tonsillar pillar.
C09.8: Malignant neoplasm of overlapping sites of tonsil- Overlapping tumor sites can impact speech mechanisms, necessitating evaluation.
C09.9: Malignant neoplasm of tonsil, unspecified- Unspecified tonsil malignancies may affect speech production.
C10.0: Malignant neoplasm of vallecula- Tumors in the vallecula can interfere with articulation and phonological processes.
C10.1: Malignant neoplasm of anterior surface of epiglottis- Speech sound production may be affected by tumors in the epiglottis.
C10.2: Malignant neoplasm of lateral wall of oropharynx- Lateral wall involvement can disrupt normal speech mechanisms.
C10.3: Malignant neoplasm of posterior wall of oropharynx- Posterior wall tumors may cause speech sound production issues.
C10.4: Malignant neoplasm of branchial cleft- Branchial cleft malignancies can impact speech articulation.
C10.8: Malignant neoplasm of overlapping sites of oropharynx- Overlapping oropharyngeal sites may affect speech production.
C10.9: Malignant neoplasm of oropharynx, unspecified- Unspecified oropharyngeal malignancies may result in speech sound disorders requiring evaluation.
Related CPT Codes
92507: Treatment of speech, language, voice, communication, and/or auditory processing disorder. Used for therapy sessions following evaluation.92508: Group therapy for speech-language pathology (when not direct one-on-one contact). Used when therapy is provided in a group setting.92521: Evaluation of speech fluency (e.g., stuttering, cluttering). Used when assessing fluency disorders, which may be performed alongside or separately from speech sound production evaluation.92523: Evaluation of speech sound production (e.g., articulation, phonological process, apraxia, dysarthria); with evaluation of language comprehension and expression (e.g., receptive and expressive language). Used when both speech sound production and language abilities are evaluated together.92524: Behavioral and qualitative analysis of voice and resonance. Used when voice and resonance issues are suspected or need assessment.
92507 and 92508 are commonly used after 92522 for treatment. 92521, 92523, and 92524 may be used as alternatives or in conjunction with 92522 depending on the patient's needs.
National Reimbursement Benchmarks
Medicare's national mean rate for CPT code 92522 is $115.58, while the BUCA (average commercial) mean rate is higher at $132.95. Among the major commercial payers, Cigna and UnitedHealth Group have the highest mean rates, at $170.32 and $157.84 respectively, with Blue Cross Blue Shield at $127.23 and Aetna at $105.87.
Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies significantly across payers. Medicare shows the tightest range at $8.00, indicating relatively consistent reimbursement rates. In contrast, Cigna exhibits the widest dispersion at $96.00, followed by UnitedHealth Group at $90.00, suggesting greater variability in commercial rates. Blue Cross Blue Shield and BUCA also show substantial ranges, at $54.00 and $64.17 respectively, while Aetna's range is $34.67.
The table and chart below present the full breakdown of national benchmarks for CPT code 92522 across all major payers.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.